Arena Defends Obesity Drug After Phase III BLOOM Wilts

Arena is playing up the robust safety profile and approvability of its obesity drug lorcaserin after unveiling lackluster efficacy results from the Phase III BLOOM trial

More from Archive

More from Pink Sheet